+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
HIV Clinical Trials Market by Drug Class, Trial Phase, End User, Route Of Administration, Distribution Channel, Patient Age Group - Global Forecast 2025-2030- Product Image
HIV Clinical Trials Market by Drug Class, Trial Phase, End User, Route Of Administration, Distribution Channel, Patient Age Group - Global Forecast 2025-2030- Product Image
Sale

HIV Clinical Trials Market by Drug Class, Trial Phase, End User, Route Of Administration, Distribution Channel, Patient Age Group - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 198 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5666075
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The HIV Clinical Trials Market is rapidly evolving, shaped by scientific innovation, regulatory strategies, and the collaborative actions of key industry stakeholders. Senior decision-makers seeking strategic guidance must consider the market’s segmented complexities, emerging technologies, and the critical role of flexible operational models.

Market Snapshot: HIV Clinical Trials Market Size and Growth

The HIV Clinical Trials Market grew from USD 1.23 billion in 2024 to USD 1.33 billion in 2025. It is expected to continue growing at a CAGR of 7.24%, reaching USD 1.88 billion by 2030. This growth highlights sustained investment in clinical research, driven by the development of novel therapeutics, evolving regulatory environments, and expanding trial networks targeting diverse populations worldwide.

Scope & Segmentation

  • Drug Classes: Entry inhibitors (enfuvirtide, maraviroc), integrase strand transfer inhibitors (bictegravir, dolutegravir, elvitegravir, raltegravir), non-nucleoside reverse transcriptase inhibitors (efavirenz, etravirine, nevirapine, rilpivirine), nucleoside reverse transcriptase inhibitors (emtricitabine, lamivudine, tenofovir, zidovudine), and protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir).
  • Trial Phases: Phase I, Phase II (with Phase IIa and IIb), Phase III, and Phase IV studies.
  • End Users: Clinics, hospitals, research institutes, including academic centers and contract research organizations.
  • Routes of Administration: Injectable, oral, and transdermal modalities.
  • Distribution Channels: Hospital, online, and retail pharmacies (chain and independent).
  • Patient Age Groups: Adult, geriatric, and pediatric populations.
  • Regions: Americas (with further market breakdown in the United States and leading Latin American economies), Europe, Middle East & Africa (spanning Western Europe, the Middle East, Sub-Saharan Africa, and Northern Europe), and Asia-Pacific (major East and Southeast Asian markets).
  • Key Companies: Gilead Sciences, ViiV Healthcare, Merck & Co., Johnson & Johnson, Roche, Pfizer, AbbVie, Sanofi, Moderna, and Takeda Pharmaceutical Company.

Key Takeaways for Senior Decision-Makers

  • Clinical trials remain central to advancing HIV therapeutics, driving progress in drug efficacy, safety, and patient outcomes, while continually adapting to complex scientific and logistical challenges.
  • Collaborative frameworks among academic researchers, contract organizations, industry sponsors, and regulatory agencies are accelerating the transition from laboratory research to patient-ready treatments, expanding global trial access.
  • Advanced digital tools and biomarker technologies are improving patient engagement, real-time data integrity, and the ability to implement adaptive trial methodologies for greater operational efficiency.
  • Companies leading the market prioritize differentiated drug pipelines and strategic alliances, supporting the ongoing evolution of next-generation therapies and trial models.
  • Decentralized and patient-centric trial designs, including remote monitoring, home-based sample collection, and telemedicine visits, are becoming essential for reducing participant burden and strengthening retention.
  • Tailoring strategies for local regulatory environments and infrastructure capacities ensures more effective trial enrollment, mitigates risk, and accelerates new therapy development.

Tariff Impact: Operational Challenges and Strategic Responses

Recent United States tariff policies have added complexity to supply chains, affecting procurement of laboratory materials and equipment for HIV clinical trials. Sponsors adjust by sourcing domestically, consolidating shipments, exploring warehousing in tariff-exempt locations, and building flexible supplier partnerships. Transparent communication with regulatory entities and proactive risk mitigation strategies help sustain uninterrupted trial progress and cost management under changing trade environments.

Methodology & Data Sources

This report draws from a systematic review of clinical trial registries, regulatory filings, and peer-reviewed publications. Structured interviews with pharmaceutical leaders, CRO executives, regulatory representatives, and clinical investigators inform key findings. Quantitative insights were refined through data analytics, regional normalization, and scenario modeling to provide actionable intelligence for executive decisions.

Why This Report Matters

  • Enables senior leaders to benchmark market positioning and identify growth opportunities by delivering a nuanced analysis of drug classes, trial phases, technologies, and geographic factors.
  • Equips decision-makers with strategic, evidence-based recommendations for optimizing trial operations, navigating tariffs, and boosting stakeholder engagement in a dynamic regulatory and competitive landscape.

Conclusion

The HIV Clinical Trials Market is poised for continued advancement through innovation, collaboration, and patient-centric strategies. Executives relying on adaptive frameworks and evidence-driven insights are best positioned to drive sustained success and resilient clinical outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of long-acting injectable antiretroviral therapies into routine HIV management to improve adherence
5.2. Advancements in broadly neutralizing antibody trials targeting diverse HIV-1 clades for broader efficacy
5.3. Implementation of decentralized clinical trial models leveraging telemedicine for enhanced patient retention in HIV studies
5.4. Development of dual-acting therapeutic vaccines aiming to both boost immunity and reduce reservoir size in HIV patients
5.5. Exploration of CRISPR-based gene editing approaches for potential functional cure in early-phase HIV clinical trials
5.6. Adoption of real-world data analytics to inform adaptive trial designs and optimize HIV drug development pipelines
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. HIV Clinical Trials Market, by Drug Class
8.1. Introduction
8.2. Entry Inhibitors
8.2.1. Enfuvirtide
8.2.2. Maraviroc
8.3. Integrase Strand Transfer Inhibitors
8.3.1. Bictegravir
8.3.2. Dolutegravir
8.3.3. Elvitegravir
8.3.4. Raltegravir
8.4. Non-Nucleoside Reverse Transcriptase Inhibitors
8.4.1. Efavirenz
8.4.2. Etravirine
8.4.3. Nevirapine
8.4.4. Rilpivirine
8.5. Nucleoside Reverse Transcriptase Inhibitors
8.5.1. Emtricitabine
8.5.2. Lamivudine
8.5.3. Tenofovir
8.5.4. Zidovudine
8.6. Protease Inhibitors
8.6.1. Atazanavir
8.6.2. Darunavir
8.6.3. Fosamprenavir
8.6.4. Lopinavir
9. HIV Clinical Trials Market, by Trial Phase
9.1. Introduction
9.2. Phase I
9.3. Phase II
9.3.1. Phase IIa
9.3.2. Phase IIb
9.4. Phase III
9.5. Phase IV
10. HIV Clinical Trials Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Hospitals
10.4. Research Institutes
10.4.1. Academic Institutes
10.4.2. Contract Research Organizations
11. HIV Clinical Trials Market, by Route Of Administration
11.1. Introduction
11.2. Injectable
11.3. Oral
11.4. Transdermal
12. HIV Clinical Trials Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
12.4.1. Chain Pharmacies
12.4.2. Independent Pharmacies
13. HIV Clinical Trials Market, by Patient Age Group
13.1. Introduction
13.2. Adult
13.3. Geriatric
13.4. Pediatric
14. Americas HIV Clinical Trials Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa HIV Clinical Trials Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific HIV Clinical Trials Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Gilead Sciences, Inc.
17.3.2. ViiV Healthcare Limited
17.3.3. Merck & Co., Inc.
17.3.4. Johnson & Johnson
17.3.5. Roche Holding AG
17.3.6. Pfizer Inc.
17.3.7. AbbVie Inc.
17.3.8. Sanofi S.A.
17.3.9. Moderna, Inc.
17.3.10. Takeda Pharmaceutical Company Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. HIV CLINICAL TRIALS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. HIV CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. HIV CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. HIV CLINICAL TRIALS MARKET: RESEARCHAI
FIGURE 28. HIV CLINICAL TRIALS MARKET: RESEARCHSTATISTICS
FIGURE 29. HIV CLINICAL TRIALS MARKET: RESEARCHCONTACTS
FIGURE 30. HIV CLINICAL TRIALS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. HIV CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENFUVIRTIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENFUVIRTIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY MARAVIROC, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY MARAVIROC, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY BICTEGRAVIR, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY BICTEGRAVIR, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DOLUTEGRAVIR, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DOLUTEGRAVIR, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ELVITEGRAVIR, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ELVITEGRAVIR, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RALTEGRAVIR, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RALTEGRAVIR, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EFAVIRENZ, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EFAVIRENZ, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ETRAVIRINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ETRAVIRINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NEVIRAPINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NEVIRAPINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RILPIVIRINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RILPIVIRINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EMTRICITABINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EMTRICITABINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LAMIVUDINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LAMIVUDINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TENOFOVIR, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TENOFOVIR, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ZIDOVUDINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ZIDOVUDINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ATAZANAVIR, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ATAZANAVIR, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DARUNAVIR, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DARUNAVIR, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY FOSAMPRENAVIR, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY FOSAMPRENAVIR, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LOPINAVIR, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LOPINAVIR, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 187. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 188. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 189. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2024 (USD MILLION)
TABLE 190. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2025-2030 (USD MILLION)
TABLE 191. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2024 (USD MILLION)
TABLE 192. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2025-2030 (USD MILLION)
TABLE 193. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 194. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 195. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 196. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 197. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 198. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 199. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2024 (USD MILLION)
TABLE 200. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025-2030 (USD MILLION)
TABLE 201. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2024 (USD MILLION)
TABLE 202. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2025-2030 (USD MILLION)
TABLE 203. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 204. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 205. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 206. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 207. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 208. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 209. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 210. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 211. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 212. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 213. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 214. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 215. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 216. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 217. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2024 (USD MILLION)
TABLE 218. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2025-2030 (USD MILLION)
TABLE 219. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2024 (USD MILLION)
TABLE 220. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2025-2030 (USD MILLION)
TABLE 221. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 222. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 223. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 224. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 225. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 226. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 227. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2024 (USD MILLION)
TABLE 228. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025-2030 (USD MILLION)
TABLE 229. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2024 (USD MILLION)
TABLE 230. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2025-2030 (USD MILLION)
TABLE 231. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 234. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 235. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 236. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 237. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 240. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 241. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 242. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 243. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 244. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 245. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2024 (USD MILLION)
TABLE 246. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2025-2030 (USD MILLION)
TABLE 247. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2024 (USD MILLION)
TABLE 248. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2025-2030 (USD MILLION)
TABLE 249. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 250. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 251. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 252. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 253. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 254. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 255. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2024 (USD MILLION)
TABLE 256. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025-2030 (USD MILLION)
TABLE 257. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2024 (USD MILLION)
TABLE 258. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2025-2030 (USD MILLION)
TABLE 259. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 260. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 261. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 262. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 263. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 264. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 265. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 268. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 269. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 270. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 271. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 272. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 273. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2024 (USD MILLION)
TABLE 274. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2025-2030 (USD MILLION)
TABLE 275. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2024 (USD MILLION)
TABLE 276. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2025-2030 (USD MILLION)
TABLE 277. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 278. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 279. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 280. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 281. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 282. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 283. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2024 (USD MILLION)
TABLE 284. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025-2030 (USD MILLION)
TABLE 285. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2024 (USD MILLION)
TABLE 286. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2025-2030 (USD MILLION)
TABLE 287. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 288. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 289. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 290. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 291. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 292. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 293. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 296. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 297. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 298. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 299. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 300. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 301. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2024 (USD MILLION)
TABLE 302. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2025-2030 (USD MILLION)
TABLE 303. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2024 (USD MILLION)
TABLE 304. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2025-2030 (USD MILLION)
TABLE 305. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 306. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 307. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 308. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 309. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 310. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 311. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2024 (USD MILLION)
TABLE 312. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025-2030 (USD MILLION)
TABLE 313. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2024 (USD MILLION)
TABLE 314. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2025-2030 (USD MILLION)
TABLE 315. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 316. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 317. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this HIV Clinical Trials market report include:
  • Gilead Sciences, Inc.
  • ViiV Healthcare Limited
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Roche Holding AG
  • Pfizer Inc.
  • AbbVie Inc.
  • Sanofi S.A.
  • Moderna, Inc.
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages198
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.33 Billion
Forecasted Market Value ( USD ) by 2030 $ 1.88 Billion
Compound Annual Growth Rate7.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

HIV Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional Studies, Observational Studies, Expanded Access Studies), By Sponsor, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

HIV Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional Studies, Observational Studies, Expanded Access Studies), By Sponsor, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
HIV Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

HIV Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
HIV Clinical Trials - Global Strategic Business Report - Product Image

HIV Clinical Trials - Global Strategic Business Report

  • Report
  • 379 Pages
  • Global
From
HIV Drugs Market Size Analysis Report - Market Share, Forecast Trends and Outlook 2025-2034 - Product Image

HIV Drugs Market Size Analysis Report - Market Share, Forecast Trends and Outlook 2025-2034

  • Report
  • 400 Pages
  • Global
From
Human Immunodeficiency Virus Therapeutics Market by Drug Class, Regimen Type, Therapy Line, Mode Of Administration, Patient Type, Distribution Channel - Global Forecast 2025-2030 - Product Image

Human Immunodeficiency Virus Therapeutics Market by Drug Class, Regimen Type, Therapy Line, Mode Of Administration, Patient Type, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From

About the HIV Clinical Trial Market

The HIV Clinical Trial market is a subset of the larger Clinical Trials market, which focuses on the development of treatments and preventative measures for HIV/AIDS. HIV Clinical Trials are conducted to evaluate the safety and efficacy of new drugs, vaccines, and other treatments for HIV/AIDS. These trials are conducted in accordance with the ethical principles of the Declaration of Helsinki and the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The HIV Clinical Trial market is highly regulated, with stringent requirements for the design, conduct, and reporting of clinical trials. The market is also subject to a variety of legal and ethical considerations, including patient privacy and informed consent. Companies in the HIV Clinical Trial market include Gilead Sciences, Merck, ViiV Healthcare, Janssen Pharmaceuticals, and GlaxoSmithKline. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.